Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1466839
This article is part of the Research Topic Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy View all 17 articles

VISTA in haematological malignancies: A review of the literature

Provisionally accepted
Yuanjia Duan Yuanjia Duan 1,2,3Xiaotong Ren Xiaotong Ren 1,2,4Xinyu Guo Xinyu Guo 1,2,3Jiayi Xie Jiayi Xie 1,2,3zhao yun Liu zhao yun Liu 1,2,3Lijuan Li Lijuan Li 1,2,3*
  • 1 Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, China
  • 2 Tianjin Institute of Hematology, Tianjin, China
  • 3 Department of Hematology, Tianjin Medical University General Hospital, 154 Anshan Street, Heping District, Tianjin, China
  • 4 Department of Hematology, Tianjin Medical University General Hospital, 154 Anshan Street, Heping District,, Tianjin, China

The final, formatted version of the article will be published soon.

    In recent years, tumour immunotherapy has become an active research area, with the emergence of immune checkpoint inhibitors (ICIs) revolutionising immunotherapy.Clinical evidence indicates that programmed cell death protein 1 (PD-1) monoclonal antibodies and other drugs have remarkable therapeutic effects. V-domain Ig suppressor of T-cell activation (VISTA) is a new type of immune checkpoint receptor that is highly expressed in various tumours. It is co-expressed with PD-1, T-cell immunoglobulin domain, mucin domain-3 (Tim-3), T-cell immunoglobulin, and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) and is associated with prognosis, which suggests that it may be a target for immunotherapy. As an immune checkpoint receptor with no mature drugs, VISTA is highly expressed in acute myeloid leukaemia (AML), multiple myeloma (MM), and other haematological malignancies; however, its pathogenic mechanism should be defined to better guide treatment.

    Keywords: immune checkpoint receptors, Vista, haematological malignancies, tumour microenvironment, Immunotherapy

    Received: 18 Jul 2024; Accepted: 29 Nov 2024.

    Copyright: © 2024 Duan, Ren, Guo, Xie, Liu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Lijuan Li, Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.